JIN MEDICAL INTERNATIONAL-A (ZJYL) Fundamental Analysis & Valuation

NASDAQ:ZJYL • KYG5140V1207

Current stock price

2.08 USD
+0.08 (+4%)
Last:

This ZJYL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ZJYL Profitability Analysis

1.1 Basic Checks

  • ZJYL had positive earnings in the past year.
  • ZJYL had a positive operating cash flow in the past year.
  • Each year in the past 5 years ZJYL has been profitable.
  • ZJYL had a positive operating cash flow in 4 of the past 5 years.
ZJYL Yearly Net Income VS EBIT VS OCF VS FCFZJYL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M 4M

1.2 Ratios

  • With a decent Return On Assets value of 2.23%, ZJYL is doing good in the industry, outperforming 74.33% of the companies in the same industry.
  • With a decent Return On Equity value of 4.02%, ZJYL is doing good in the industry, outperforming 74.87% of the companies in the same industry.
  • ZJYL's Return On Invested Capital of 1.06% is fine compared to the rest of the industry. ZJYL outperforms 67.91% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ZJYL is below the industry average of 9.12%.
  • The 3 year average ROIC (5.77%) for ZJYL is well above the current ROIC(1.06%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 2.23%
ROE 4.02%
ROIC 1.06%
ROA(3y)6.33%
ROA(5y)8.79%
ROE(3y)9.59%
ROE(5y)13.06%
ROIC(3y)5.77%
ROIC(5y)8.97%
ZJYL Yearly ROA, ROE, ROICZJYL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • ZJYL has a Profit Margin of 5.76%. This is in the better half of the industry: ZJYL outperforms 78.61% of its industry peers.
  • ZJYL's Profit Margin has declined in the last couple of years.
  • With a decent Operating Margin value of 2.94%, ZJYL is doing good in the industry, outperforming 68.45% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ZJYL has declined.
  • ZJYL's Gross Margin of 29.22% is on the low side compared to the rest of the industry. ZJYL is outperformed by 74.33% of its industry peers.
  • In the last couple of years the Gross Margin of ZJYL has declined.
Industry RankSector Rank
OM 2.94%
PM (TTM) 5.76%
GM 29.22%
OM growth 3Y-35.79%
OM growth 5Y-27.37%
PM growth 3Y-25.82%
PM growth 5Y-15.82%
GM growth 3Y-3.29%
GM growth 5Y-2.96%
ZJYL Yearly Profit, Operating, Gross MarginsZJYL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ZJYL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ZJYL is creating some value.
  • ZJYL has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ZJYL has been reduced compared to 5 years ago.
  • The debt/assets ratio for ZJYL is higher compared to a year ago.
ZJYL Yearly Shares OutstandingZJYL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
ZJYL Yearly Total Debt VS Total AssetsZJYL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 1.90 indicates that ZJYL is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a Altman-Z score value of 1.90, ZJYL perfoms like the industry average, outperforming 57.22% of the companies in the same industry.
  • ZJYL has a Debt/Equity ratio of 0.64. This is a neutral value indicating ZJYL is somewhat dependend on debt financing.
  • The Debt to Equity ratio of ZJYL (0.64) is worse than 67.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z 1.9
ROIC/WACC0.21
WACC4.97%
ZJYL Yearly LT Debt VS Equity VS FCFZJYL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

  • ZJYL has a Current Ratio of 1.86. This is a normal value and indicates that ZJYL is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of ZJYL (1.86) is worse than 67.91% of its industry peers.
  • A Quick Ratio of 1.65 indicates that ZJYL should not have too much problems paying its short term obligations.
  • ZJYL has a Quick ratio (1.65) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.65
ZJYL Yearly Current Assets VS Current LiabilitesZJYL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ZJYL Growth Analysis

3.1 Past

  • ZJYL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -66.94%.
  • Measured over the past years, ZJYL shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.83% on average per year.
  • Looking at the last year, ZJYL shows a very negative growth in Revenue. The Revenue has decreased by -11.98% in the last year.
  • ZJYL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.02% yearly.
EPS 1Y (TTM)-66.94%
EPS 3Y-22.74%
EPS 5Y-10.83%
EPS Q2Q%-31.95%
Revenue 1Y (TTM)-11.98%
Revenue growth 3Y2.53%
Revenue growth 5Y5.02%
Sales Q2Q%-16.53%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZJYL Yearly Revenue VS EstimatesZJYL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

2

4. ZJYL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 13.87, which indicates a correct valuation of ZJYL.
  • Based on the Price/Earnings ratio, ZJYL is valued cheaply inside the industry as 89.84% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of ZJYL to the average of the S&P500 Index (27.89), we can say ZJYL is valued rather cheaply.
Industry RankSector Rank
PE 13.87
Fwd PE N/A
ZJYL Price Earnings VS Forward Price EarningsZJYL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -42.44
ZJYL Per share dataZJYL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZJYL Dividend Analysis

5.1 Amount

  • ZJYL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZJYL Fundamentals: All Metrics, Ratios and Statistics

JIN MEDICAL INTERNATIONAL-A

NASDAQ:ZJYL (4/20/2026, 2:57:01 PM)

2.08

+0.08 (+4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.29%
Inst Owner Change-0.04%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.29M
Revenue(TTM)20.69M
Net Income(TTM)1.19M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 13.87
Fwd PE N/A
P/S 0.79
P/FCF N/A
P/OCF 5.61
P/B 0.55
P/tB 0.57
EV/EBITDA -42.44
EPS(TTM)0.15
EY7.21%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)0.37
OCFY17.83%
SpS2.64
BVpS3.79
TBVpS3.64
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.57426 (71.84%)
Profitability
Industry RankSector Rank
ROA 2.23%
ROE 4.02%
ROCE 2.06%
ROIC 1.06%
ROICexc 2.73%
ROICexgc 2.9%
OM 2.94%
PM (TTM) 5.76%
GM 29.22%
FCFM N/A
ROA(3y)6.33%
ROA(5y)8.79%
ROE(3y)9.59%
ROE(5y)13.06%
ROIC(3y)5.77%
ROIC(5y)8.97%
ROICexc(3y)15.69%
ROICexc(5y)19.14%
ROICexgc(3y)16.58%
ROICexgc(5y)19.88%
ROCE(3y)8.9%
ROCE(5y)11.89%
ROICexgc growth 3Y-49.44%
ROICexgc growth 5Y-31.36%
ROICexc growth 3Y-50.12%
ROICexc growth 5Y-31.95%
OM growth 3Y-35.79%
OM growth 5Y-27.37%
PM growth 3Y-25.82%
PM growth 5Y-15.82%
GM growth 3Y-3.29%
GM growth 5Y-2.96%
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA 22.12
Cap/Depr 2723.83%
Cap/Sales 32.05%
Interest Coverage 1.48
Cash Conversion 340.96%
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.65
Altman-Z 1.9
F-Score4
WACC4.97%
ROIC/WACC0.21
Cap/Depr(3y)1082.33%
Cap/Depr(5y)654.09%
Cap/Sales(3y)12.47%
Cap/Sales(5y)7.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.94%
EPS 3Y-22.74%
EPS 5Y-10.83%
EPS Q2Q%-31.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.98%
Revenue growth 3Y2.53%
Revenue growth 5Y5.02%
Sales Q2Q%-16.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-83.29%
EBIT growth 3Y-34.16%
EBIT growth 5Y-23.72%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-59.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y340.5%
OCF growth 3Y22.47%
OCF growth 5Y3.01%

JIN MEDICAL INTERNATIONAL-A / ZJYL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for JIN MEDICAL INTERNATIONAL-A?

ChartMill assigns a fundamental rating of 3 / 10 to ZJYL.


What is the valuation status for ZJYL stock?

ChartMill assigns a valuation rating of 2 / 10 to JIN MEDICAL INTERNATIONAL-A (ZJYL). This can be considered as Overvalued.


How profitable is JIN MEDICAL INTERNATIONAL-A (ZJYL) stock?

JIN MEDICAL INTERNATIONAL-A (ZJYL) has a profitability rating of 5 / 10.


What is the valuation of JIN MEDICAL INTERNATIONAL-A based on its PE and PB ratios?

The Price/Earnings (PE) ratio for JIN MEDICAL INTERNATIONAL-A (ZJYL) is 13.87 and the Price/Book (PB) ratio is 0.55.